{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:15:40Z","timestamp":1791512140757,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1245\/s10434-026-19196-x","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:30:54Z","timestamp":1772296254000},"page":"5387-5398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and Survival Outcomes of Neoadjuvant Chemoradiotherapy Combined with Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Real-World Analysis (NEO-EC-01)"],"prefix":"10.1245","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct06828718","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ke","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pudong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"issue":"8","key":"19196_CR1","doi-asserted-by":"publisher","first-page":"656","DOI":"10.20892\/j.issn.2095-3941.2024.0145","volume":"21","author":"Y Teng","year":"2024","unstructured":"Teng Y, Xia C, Cao M, et al. Esophageal cancer global burden profiles, trends, and contributors. Cancer Biol Med. 2024;21(8):656\u201366. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2024.0145.","journal-title":"Cancer Biol Med."},{"issue":"25","key":"19196_CR2","doi-asserted-by":"publisher","first-page":"00314","DOI":"10.1016\/j.jare.2025.05.021","volume":"S2090\u20131232","author":"Y Jiao","year":"2025","unstructured":"Jiao Y, Wang T, Fu L, et al. Trends, patterns, and risk factors of esophageal cancer mortality in China, 2008\u20132021: a national mortality surveillance system data analysis. J Adv Res. 2025;S2090\u20131232(25):00314\u20135. https:\/\/doi.org\/10.1016\/j.jare.2025.05.021.","journal-title":"J Adv Res."},{"issue":"23","key":"19196_CR3","doi-asserted-by":"publisher","first-page":"5604","DOI":"10.3390\/cancers15235604","volume":"15","author":"E Conway","year":"2023","unstructured":"Conway E, Wu H, Tian L. Overview of risk factors for esophageal squamous cell carcinoma in china. Cancers (Basel). 2023;15(23):5604. https:\/\/doi.org\/10.3390\/cancers15235604.","journal-title":"Cancers (Basel)."},{"issue":"9","key":"19196_CR4","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/s1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090\u20138. https:\/\/doi.org\/10.1016\/s1470-2045(15)00040-6.","journal-title":"Lancet Oncol."},{"key":"19196_CR5","doi-asserted-by":"publisher","first-page":"1310073","DOI":"10.3389\/fonc.2024.1310073","volume":"14","author":"G Liu","year":"2024","unstructured":"Liu G, Hu B, Chen T, et al. Recurrence timing and patterns incorporating lymph node status after neoadjuvant chemoradiotherapy plus esophagectomy for esophageal squamous cell carcinoma. Front Oncol. 2024;14:1310073. https:\/\/doi.org\/10.3389\/fonc.2024.1310073.","journal-title":"Front Oncol."},{"issue":"10","key":"19196_CR6","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1245\/s10434-024-15678-y","volume":"31","author":"JY Kim","year":"2024","unstructured":"Kim JY, Yun JK, Kim YH, et al. Prognostic impact of inflammation-based factors in patients with esophageal squamous cell carcinoma achieving pathological complete response after neoadjuvant chemoradiotherapy followed by surgery. Ann Surg Oncol. 2024;31(10):6662\u201372. https:\/\/doi.org\/10.1245\/s10434-024-15678-y.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"19196_CR7","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1186\/s12885-021-08918-x","volume":"21","author":"Y Nagaki","year":"2021","unstructured":"Nagaki Y, Motoyama S, Sato Y, et al. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy. BMC Cancer. 2021;21(1):1192. https:\/\/doi.org\/10.1186\/s12885-021-08918-x.","journal-title":"BMC Cancer."},{"issue":"10302","key":"19196_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(21)01234-4.","journal-title":"Lancet."},{"issue":"5","key":"19196_CR9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24(5):483\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(23)00108-0.","journal-title":"Lancet Oncol."},{"issue":"10","key":"19196_CR10","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.ccell.2024.09.008","volume":"42","author":"X Shang","year":"2024","unstructured":"Shang X, Xie Y, Yu J, et al. A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: the Keystone-001 trial. Cancer Cell. 2024;42(10):1747-1763.e7. https:\/\/doi.org\/10.1016\/j.ccell.2024.09.008.","journal-title":"Cancer Cell."},{"issue":"7","key":"19196_CR11","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/s41416-024-02805-5","volume":"131","author":"YY Chen","year":"2024","unstructured":"Chen YY, Wang PP, Hu Y, et al. Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial. Br J Cancer. 2024;131(7):1126\u201336. https:\/\/doi.org\/10.1038\/s41416-024-02805-5.","journal-title":"Br J Cancer."},{"issue":"10","key":"19196_CR12","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/cac2.12604","volume":"44","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Liang G, Yuan D, et al. Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial. Cancer Commun (Lond). 2024;44(10):1214\u201327. https:\/\/doi.org\/10.1002\/cac2.12604.","journal-title":"Cancer Commun (Lond)."},{"issue":"8","key":"19196_CR13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamasurg.2021.2373","volume":"156","author":"H Yang","year":"2021","unstructured":"Yang H, Liu H, Chen Y, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial. JAMA Surg. 2021;156(8):721\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2021.2373.","journal-title":"JAMA Surg."},{"issue":"3","key":"19196_CR14","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.21873\/anticanres.13259","volume":"39","author":"Y Hamai","year":"2019","unstructured":"Hamai Y, Emi M, Ibuki Y, et al. Early recurrence and cancer death after trimodal therapy for esophageal squamous cell carcinoma. Anticancer Res. 2019;39(3):1433\u201340. https:\/\/doi.org\/10.21873\/anticanres.13259.","journal-title":"Anticancer Res."},{"issue":"2","key":"19196_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.semradonc.2019.12.005","volume":"30","author":"A Brandmaier","year":"2020","unstructured":"Brandmaier A, Formenti SC. The impact of radiation therapy on innate and adaptive tumor immunity. Semin Radiat Oncol. 2020;30(2):139\u201344. https:\/\/doi.org\/10.1016\/j.semradonc.2019.12.005.","journal-title":"Semin Radiat Oncol"},{"key":"19196_CR16","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.3389\/fimmu.2018.03077","volume":"9","author":"TB Dar","year":"2019","unstructured":"Dar TB, Henson RM, Shiao SL. Targeting innate immunity to enhance the efficacy of radiation therapy. Front Immunol. 2019;9:3077. https:\/\/doi.org\/10.3389\/fimmu.2018.03077.","journal-title":"Front Immunol."},{"issue":"12","key":"19196_CR17","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1007\/s00066-023-02103-8","volume":"199","author":"S Classen","year":"2023","unstructured":"Classen S, Petersen C, Borgmann K. Crosstalk between immune checkpoint and DNA damage response inhibitors for radiosensitization of tumors. Strahlenther Onkol. 2023;199(12):1152\u201363. https:\/\/doi.org\/10.1007\/s00066-023-02103-8.","journal-title":"Strahlenther Onkol."},{"issue":"6","key":"19196_CR18","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1158\/1078-0432.CCR-18-2581","volume":"25","author":"Y Wang","year":"2019","unstructured":"Wang Y, Liu ZG, Yuan H, et al. The reciprocity between radiotherapy and cancer immunotherapy. Clin Cancer Res. 2019;25(6):1709\u201317. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2581.","journal-title":"Clin Cancer Res."},{"issue":"3","key":"19196_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008631","volume":"12","author":"X Xu","year":"2024","unstructured":"Xu X, Sun Z, Liu Q, et al. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer. J Immunother Cancer. 2024;12(3):e008631. https:\/\/doi.org\/10.1136\/jitc-2023-008631.","journal-title":"J Immunother Cancer."},{"key":"19196_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102118","volume":"62","author":"R Chen","year":"2023","unstructured":"Chen R, Liu Q, Li Q, et al. A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901). EClinicalMedicine. 2023;62:102118. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102118.","journal-title":"EClinicalMedicine."},{"issue":"3","key":"19196_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004291","volume":"10","author":"J Liu","year":"2022","unstructured":"Liu J, Yang Y, Liu Z, et al. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10(3):e004291. https:\/\/doi.org\/10.1136\/jitc-2021-004291.","journal-title":"J Immunother Cancer."},{"issue":"3","key":"19196_CR22","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jtcvs.2023.08.056","volume":"167","author":"Y Yang","year":"2024","unstructured":"Yang Y, Liu J, Liu Z, et al. Two-year outcomes of clinical N2\u20133 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study. J Thorac Cardiovasc Surg. 2024;167(3):838-847.e1. https:\/\/doi.org\/10.1016\/j.jtcvs.2023.08.056.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"1","key":"19196_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtcvs.2024.06.020","volume":"169","author":"X Yang","year":"2025","unstructured":"Yang X, Yin H, Zhang S, et al. Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2025;169(1):289-300.e6. https:\/\/doi.org\/10.1016\/j.jtcvs.2024.06.020.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"27","key":"19196_CR24","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","volume":"36","author":"H Yang","year":"2018","unstructured":"Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018;36(27):2796\u2013803. https:\/\/doi.org\/10.1200\/JCO.2018.79.1483.","journal-title":"J Clin Oncol."},{"issue":"1","key":"19196_CR25","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1186\/s12885-024-12774-w","volume":"24","author":"WX Qi","year":"2024","unstructured":"Qi WX, Li S, Li H, Chen J, Zhao S. The addition of pembrolizumab to neoadjuvant chemoradiotherapy did not increase the risk of developing postoperative anastomotic leakage for ESCC: an analysis from a prospective cohort. BMC Cancer. 2024;24(1):1029. https:\/\/doi.org\/10.1186\/s12885-024-12774-w.","journal-title":"BMC Cancer."},{"issue":"4","key":"19196_CR26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.ijrobp.2016.11.054","volume":"97","author":"M Ko\u00ebter","year":"2017","unstructured":"Ko\u00ebter M, Kathiravetpillai N, Gooszen JA, et al. Influence of the extent and dose of radiation on complications after neoadjuvant chemoradiation and subsequent esophagectomy with gastric tube reconstruction with a cervical anastomosis. Int J Radiat Oncol Biol Phys. 2017;97(4):813\u201321. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.11.054.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"5","key":"19196_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00280-019-03944-w","volume":"84","author":"S Qi","year":"2019","unstructured":"Qi S, Mao Y, Jiang M. A phase I study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer. Cancer Chemother Pharmacol. 2019;84(5):1115\u201323. https:\/\/doi.org\/10.1007\/s00280-019-03944-w.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"11","key":"19196_CR28","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1007\/s12094-016-1488-y","volume":"18","author":"M Caro","year":"2016","unstructured":"Caro M, Font A, Comas S, et al. Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinoma. Clin Transl Oncol. 2016;18(11):1106\u201313. https:\/\/doi.org\/10.1007\/s12094-016-1488-y.","journal-title":"Clin Transl Oncol."},{"issue":"8","key":"19196_CR29","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1245\/s10434-023-14809-1","volume":"31","author":"YY Wu","year":"2024","unstructured":"Wu YY, Dai L, Yang YB, et al. Long-term survival and recurrence patterns in locally advanced esophageal squamous cell carcinoma patients with pathologic complete response after neoadjuvant chemotherapy followed by surgery. Ann Surg Oncol. 2024;31(8):5047\u201354. https:\/\/doi.org\/10.1245\/s10434-023-14809-1.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"19196_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2025.0220","volume":"160","author":"X Guo","year":"2025","unstructured":"Guo X, Chen C, Zhao J, et al. Neoadjuvant chemoradiotherapy vs chemoimmunotherapy for esophageal squamous cell carcinoma. JAMA Surg. 2025;160(5):565\u201374. https:\/\/doi.org\/10.1001\/jamasurg.2025.0220.","journal-title":"JAMA Surg."},{"issue":"2","key":"19196_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3978\/j.issn.2078-6891.2015.080","volume":"7","author":"J Hyder","year":"2016","unstructured":"Hyder J, Boggs DH, Hanna A, Suntharalingam M, Chuong MD. Changes in neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios during chemoradiation predict for survival and pathologic complete response in trimodality esophageal cancer patients. J Gastrointest Oncol. 2016;7(2):189\u201395. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2015.080.","journal-title":"J Gastrointest Oncol."},{"issue":"1","key":"19196_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.17305\/bjbms.2022.7696","volume":"23","author":"J Feng","year":"2023","unstructured":"Feng J, Wang L, Yang X, Chen Q, Cheng X. Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: a real-world study. Biomol Biomed. 2023;23(1):153\u201360. https:\/\/doi.org\/10.17305\/bjbms.2022.7696.","journal-title":"Biomol Biomed."},{"issue":"2","key":"19196_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2174\/156800912799095144","volume":"12","author":"SA Kono","year":"2012","unstructured":"Kono SA, Heasley LE, Doebele RC, Camidge DR. Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets. 2012;12(2):107\u201323. https:\/\/doi.org\/10.2174\/156800912799095144.","journal-title":"Curr Cancer Drug Targets."},{"issue":"2","key":"19196_CR34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1538-7836.2010.04131.x","volume":"9","author":"NM Bambace","year":"2011","unstructured":"Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9(2):237\u201349. https:\/\/doi.org\/10.1111\/j.1538-7836.2010.04131.x.","journal-title":"J Thromb Haemost."},{"key":"19196_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40425-016-0202-5","volume":"5","author":"L Conforti","year":"2017","unstructured":"Conforti L. Potassium channels of T lymphocytes take center stage in the fight against cancer. J Immunother Cancer. 2017;5:2. https:\/\/doi.org\/10.1186\/s40425-016-0202-5.","journal-title":"J Immunother Cancer."},{"issue":"13","key":"19196_CR36","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191\u2013203. https:\/\/doi.org\/10.1056\/NEJMoa2032125.","journal-title":"N Engl J Med."},{"issue":"4","key":"19196_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70021","volume":"16","author":"D Liu","year":"2025","unstructured":"Liu D, Liu A, Guo L, et al. Postoperative adjuvant therapy benefits non-pCR patients rather than pCR patients for locally advanced ESCC: a multicenter real-world study. Thorac Cancer. 2025;16(4):e70021. https:\/\/doi.org\/10.1111\/1759-7714.70021.","journal-title":"Thorac Cancer."},{"issue":"6","key":"19196_CR38","doi-asserted-by":"publisher","first-page":"e1022","DOI":"10.1097\/SLA.0000000000003727","volume":"274","author":"X Leng","year":"2021","unstructured":"Leng X, He W, Yang H, et al. Prognostic impact of postoperative lymph node metastases after neoadjuvant chemoradiotherapy for locally advanced squamous cell carcinoma of esophagus: from the results of NEOCRTEC5010, a randomized multicenter study. Ann Surg. 2021;274(6):e1022\u20139. https:\/\/doi.org\/10.1097\/SLA.0000000000003727.","journal-title":"Ann Surg."},{"issue":"10","key":"19196_CR39","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00262-025-04168-z","volume":"74","author":"Y Huang","year":"2025","unstructured":"Huang Y, Lin X, Fang C, et al. Impact of lymph node dissection on survival after neoadjuvant immunochemotherapy for esophageal squamous cell cancer: a double-center real-world retrospective study. Cancer Immunol Immunother. 2025;74(10):303. https:\/\/doi.org\/10.1007\/s00262-025-04168-z.","journal-title":"Cancer Immunol Immunother."},{"key":"19196_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217902","volume":"631","author":"H Zhang","year":"2025","unstructured":"Zhang H, Wang Z, Song N, et al. NCF2 drives tumor progression and metastasis through NR2F2\/LATS2\/YAP1 axis in esophageal squamous cell carcinoma. Cancer Lett. 2025;631:217902. https:\/\/doi.org\/10.1016\/j.canlet.2025.217902.","journal-title":"Cancer Lett."},{"issue":"1","key":"19196_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s12276-024-01369-x","volume":"57","author":"W Guo","year":"2025","unstructured":"Guo W, Zhou B, Dou L, et al. Single-cell RNA sequencing and spatial transcriptomics of esophageal squamous cell carcinoma with lymph node metastases. Exp Mol Med. 2025;57(1):59\u201371. https:\/\/doi.org\/10.1038\/s12276-024-01369-x.","journal-title":"Exp Mol Med."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19196-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19196-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19196-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:28:44Z","timestamp":1778869724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19196-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["19196"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19196-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ke Yan, Zixiao Wu, Xinyi Liu, Yatian Liu, Pudong Qian, Min Gao, Xiaobin Wang, Xuehan Guo, and Wenbin Shen declare no conflicts of interest that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}